Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 4 - You Need To See This

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

Evening Standard

Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site

The investment had been set to create 1,000 jobs

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding

The Guardian - UK

Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister

The Conservatives said Merck’s decision should send alarm bells ringing across Government.

Evening Standard

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

Benzinga

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca, Corning And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.

Benzinga

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating baxdrostat. The company released the topline data in July.

Benzinga

New blood pressure pill ‘lowers risk of heart problems in 12 weeks’

IN FULL

The Independent UK

The new daily pill that lowers high blood pressure by ‘spectacular’ amounts

Baxdrostat, developed by AstraZeneca, could help 10 million people worldwide

The Independent UK

New daily pill offers hope for millions with hard to control high blood pressure

A phase III trial of Baxdrostat showed it significantly lowered blood pressure in patients whose levels remained high despite being on other drugs.

The Independent UK

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Drugmakers reject health secretary’s latest offer, meaning ‘unsustainable’ rebate scheme will stay in place

The Guardian - UK

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

EuroMillions Result: 5 Stocks the £210M Lottery Winner Could Consider

French ticket-holder wins £210M EuroMillions on 19 Aug 2025, beating UK records. Grow wealth with AstraZeneca, Unilever, Shell, Microsoft, HSBC

Evening Standard

Top executive pay in UK’s biggest firms hits new record as more take home £10m

Median pay for chief executive officers of FTSE 100 companies was £4.58 million in the 2024-2025 financial year.

The Independent UK

Top executives’ pay in UK hits record high – reaching 122 times of average worker

It marks the fourth year in a row that chief executives have taken home a record amount

The Independent UK

You can now give yourself an at-home flu vaccine

The nasal spray has been approved by the FDA since 2003

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

The Guardian - UK

Shares in European drug companies hit four-month low as Trump tariffs loom

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

The Guardian - UK

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

Evening Standard

FTSE 100 climbs as earnings cascade brings cheer

Shares of Games Workshop, AstraZeneca, Barclays and Entain moved higher.

The Guardian - UK

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Evening Standard

Cancer drug demand drives higher sales for AstraZeneca

Revenues from oncology products made up 43% of the company’s total sales.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.